ArticleJournal of molecular neuroscience : MN2012
Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.
Article in Journal of molecular neuroscience : MN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 78 citations in OpenAlex.
- TSG-6 Protects Against Cerebral Ischemia-Reperfusion Injury via Upregulating Hsp70-1B in Astrocytes.CNS neuroscience & therapeutics · 2025Article
- Stem cell extracellular vesicles: a new dawn for anti-inflammatory treatment of neurodegenerative diseases.Frontiers in aging neuroscience · 2025Review
- Transverse Myelitis Successfully Treated with Posterior Decompression Followed by Secretome and Mesenchymal Stem Cell Therapy.European journal of case reports in internal medicine · 2025Article
- Human Umbilical Cord-Mesenchymal Stem Cells Promote Extracellular Matrix Remodeling in Microglia.Cells · 2024Article
- MSC-Based Cell Therapy in Neurological Diseases: A Concise Review of the Literature in Pre-Clinical and Clinical Research.Biomolecules · 2024Review
- Stem cell therapies: a new era in the treatment of multiple sclerosis.Frontiers in neurology · 2024Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders.International journal of molecular sciences · 2022Review
- Review
- The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases.Stem cell research & therapy · 2021Review
- Review
- Application of cattle placental stem cells for treating ovarian follicular cyst.World journal of stem cells · 2020Article
- Multipotency of mouse trophoblast stem cells.Stem cell research & therapy · 2020Article
- Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications.International journal of molecular sciences · 2019Review
- Intravenous C16 and angiopoietin-1 improve the efficacy of placenta-derived mesenchymal stem cell therapy for EAE.Scientific reports · 2018Article
- Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis.International journal of molecular sciences · 2018Review
- Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer's Disease.BioMed research international · 2018Review
- Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem Cell-Based Therapy for Autoimmune and Inflammatory Diseases.Frontiers in immunology · 2018Review
- Placenta-Derived Adherent Stromal Cell Therapy for Hematopoietic Disorders: A Case Study of PLX-R18.Cell transplantation · 2018Article
- Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.Stem cell reviews and reports · 2017Review
- Placental Stromal Cell Therapy for Experimental Autoimmune Encephalomyelitis: The Role of Route of Cell Delivery.Stem cells translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell-based regenerative medicine raises great hope for the treatment of multiple sclerosis (MS). Bone marrow-derived mesenchymal stem cells (BM-MSCs) are being tested in clinical trials. Bone marrow is the traditional source of human MSCs, but human term placenta appears to be an excellent alternative because of its availability, without ethical issues. In this study, the therapeutic effect of human placental MSCs (PL-MSCs) was evaluated in experimental autoimmune encephalomyelitis (EAE), the mice model of MS. EAE mice were transplanted intra-cerebrally with PL-MSCs or with the vehicle saline 5 or 10 days after first MOG injection. The mice were monitored for a month after therapy. A daily EAE score revealed a decrease in disease severity in the transplanted animals when compared to saline. Survival was significantly higher in the transplanted animals. In vitro experiments demonstrated that conditioned media from LPS-activated astrocytes stimulated PL-MSCs to express the gene TNF-α-stimulated gene/protein 6 (TSG-6). The same mRNA expression was obtained when PL-MSCs were exposed to TNF-α or IL1-β. These results demonstrate that PL-MSCs have a therapeutic effect in the EAE mice model. We assume that this effect is caused by reduction of the anti-inflammatory protein, TSG-6, of the inflammatory damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.